← boardnext 2026-09-30
CCCC
C4 Therapeutics, Inc.distress 5/10 · elevated risk$3.69-1%today-21% from 52w high
Oncology 1
Lead: multiple myeloma · est. market ~$25B (approx, global)
Revenue
pre-revenue
Liquidity
$378M
Runway
4.0 yrs
Shares 1y
+55%
Price & events
+69.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
+3.0%
1W
-12.6%
1M
+24.1%
3M
+71.5%
6M
+52.3%
1Y
-43.1%
2Y
-91.0%
5Y
-88.5%
All
Overview
- Market Cap
- $407.64M
- Volume
- 125.44K
- 52 Week Range
- $1.71 – $4.67
- Total Shares
- 110.57M
- Float Shares
- 83.71M
- Short %
- 22.76%
- % Held by Insiders
- 0.93%
- % Held by Institutions
- 85.31%
- RVOL
- 0.03x
- Beta
- 2.91
Pipeline stages · 2 programs
Cemsidomide, Dexamethasone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
CFT1946, Trametinib, Cetuximab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 3 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09-30 Estimated 50% readout ~2026-10-30 | Phase 1 | cemsidomide, Dexamethasone Oral | Multiple Myeloma, Lymphoma, Non-Hodgkin's | — | active not recruiting |
| 2028-12 Estimated 50% readout ~2028-12-31 | Phase 1 | Cemsidomide, Elranatamab | Multiple Myeloma (MM) | — | recruiting |
| 2030-03 Estimated 50% readout ~2030-04-15 | Phase 2 | Cemsidomide, Dexamethasone | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | — | recruiting |
| 2025-11-05 | Phase 1 | CFT1946, Trametinib, Cetuximab | Solid Tumors, Melanoma, NSCLC, CRC, ATC | 89 | completed |
Catalyst news & presentations · 10
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- EHA 2026 Congressconferencedata presentationsecondaryPhase 1cemsidomide · Further analysis from fully enrolled Phase 1 trial to be presented at EHA 2026 Congress.SEC 8-K
- 2026-04-08partnershipdegrader-antibody conjugates · Exclusive license to Roche for two undisclosed oncology targets; $20M upfront, >$1B potential milestones, tiered royalties.SEC 8-K
- early 2026trial initiationsecondarycemsidomide · Initiate next phase of development for cemsidomideSEC 8-K
- October 16, 2025conferencedata presentationsecondaryPhase 1cemsidomide · Presentation of Phase 1 clinical trial dataSEC 8-K
- 2025-10-01partnershipcemsidomide, elranatamab · Entered clinical trial collaboration and supply agreement with Pfizer for an upcoming Phase 1b multiple myeloma trial.SEC 8-K
- completed as of data cutoff July 23, 2025enrollment completesecondaryPhase 1cemsidomide · Completed enrollment and dose escalation for Phase 1 trial in MM and NHLSEC 8-K
- mid-year 2025regulatory submissionFiled (NDA/BLA)cemsidomide · Receive regulatory feedback on registrational development for cemsidomideSEC 8-K
- Wednesday, January 15, 2025 at 2:15 pm PSTconferencedata presentationsecondaryPresentation at 43rd Annual J.P. Morgan Healthcare ConferenceSEC 8-K
- December 8, 2024conferencedata presentationsecondaryPhase 1/2cemsidomide · Presented clinical data from ongoing Phase 1/2 trial at ASH Annual MeetingSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $13 (+262% upside) · 6 analysts
- 2026-06-01Evercore ISI GroupOutperform
- 2026-02-27BarclaysOverweight
- 2026-02-23Brookline CapitalBuy
- 2025-12-17BarclaysOverweight
- 2025-12-02TD CowenBuy
- 2025-09-23Wells FargoOverweight
Competitors — multiple myeloma
- JNJJOHNSON & JOHNSON$617.4B · D0
- ABBVAbbVie Inc.$451.1B · D2
- GSKGSK plc$217.0B · D1
- PFEPFIZER INC$142.2B · D3
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- REGNREGENERON PHARMACEUTICALS, INC.$60.4B · D2
- DTILPRECISION BIOSCIENCES INC$185M · D6
- CRBUCaribou Biosciences, Inc.$160M · D0
- TPSTTempest Therapeutics, Inc.$14M · D10
- AZNASTRAZENECA PLC— · D3
Recent news
- 2026-07-20C4 Therapeutics (CCCC) AGM 2026 Summary - Quartr
- 2026-07-13C4 Therapeutics (NASDAQ: CCCC) CMO gains shares via RSU vesting, withholds some for taxes - Stock Titan
- 2026-07-07Is C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
- 2026-07-03C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know - Yahoo Finance
- 2026-07-03C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher? - Yahoo Finance
- 2026-07-02Director at C4 Therapeutics (CCCC) takes 3,341 shares as fees - Stock Titan
- 2026-07-02Director of C4 Therapeutics (NASDAQ: CCCC) receives 2,650-share stock award - Stock Titan
- 2026-07-01Enterprise value to revenue forward of C4 Therapeutics, Inc. – NASDAQ:CCCC - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.